LNC Therapeutics acquires rights to develop Christensenella-based therapy for mood disorders 21-Apr-2020 By Will Chu French biotech firm LNC Therapeutics is to enter into a licence agreement with the University of Valencia for a patent outlining the Christensenella gut bacteria's role in addressing mood disorders.